/cdn.vox-cdn.com/uploads/chorus_asset/file/24931350/236792_iPhone_15_Pro_and_15_Pro_Max_product_photos_AJohnson_0006.jpg)
/cdn.vox-cdn.com/uploads/chorus_asset/file/24939160/tsm_roster.png)
/cdn.vox-cdn.com/uploads/chorus_asset/file/10329943/jbareham_180301_2346_nintendo_switch_0034_splatoon.jpg)
Biomea Fusion Inc., a clinical-stage biopharmaceutical company, was recently given a price target raise to $33 by EF Hutton, up from their previous target of $31. The company is primarily focused on developing and commercializing precision therapies for genomically defined cancers. The price target raise is thought to be based on the recent progress Biomea Fusion has made in its various clinical trials.
One of Biomea Fusion’s main product candidates is BMF-219, which is being developed as a treatment for patients with solid tumors that harbor NRG1 gene fusions. In December of 2021, the company presented positive data from a Phase 1 study of the drug at the American Society of Clinical Oncology (ASCO). The study demonstrated that BMF-219 was well-tolerated with encouraging early efficacy signals. These positive results were likely a key factor in EF Hutton’s price target raise.
Biomea Fusion is also developing another drug called BMF-673, which is being developed as a PARP inhibitor for the treatment of patients with solid tumors. In November of 2021, the company presented early data from a Phase 1 study of BMF-673 at the Molecular Targets and Cancer Therapeutics conference. The results of the study showed that the drug was well-tolerated and demonstrated preliminary evidence of anti-tumor activity in patients with advanced solid tumors.
Another reason Biomea Fusion received a price target raise is due to the company’s recent partnership with Roche. In October of 2021, Biomea Fusion announced that it had entered into a global license and collaboration agreement with Roche. Under the terms of the agreement, Roche will take over the development and commercialization of Biomea Fusion’s NRG1 fusion inhibitors, including BMF-219.
In summary, Biomea Fusion Inc. has received a price target raise from EF Hutton due to the company’s recent progress in its various clinical trials, including positive data from a Phase 1 study of BMF-219 and early data from a Phase 1 study of BMF-673. Additionally, the company’s partnership with Roche has also likely played a role in the price target raise. With these developments, Biomea Fusion is continuing to position itself as a potentially strong player in the precision medicine space.
Source link
